Unmet needs remain in the treatment of chronic phase chronic myeloid leukemia (CML) in later lines. Sequential use of tyrosine kinase inhibitors (TKIs) is associated with decreased overall survival and emergence of new mutations, particularly the T315I mutation. Among the new drugs developed to overcome resistance and intolerance, the STAMP inhibitor asciminib (which specifically targets the ABL myristoyl pocket) is the first example of a drug that works by allosteric inhibition. This review focuses on its mechanism of action, pharmacokinetic, efficacy, and toxicity, as well as how this drug will change the therapeutic approach for CML patients not eligible to receive other available drugs.

Asciminib as a third line option in chronic myeloid leukemia / Laganà, Alessandro; Scalzulli, Emilia; Carmosino, Ida; Martelli, Maurizio; Breccia, Massimo. - In: INTERNATIONAL JOURNAL OF HEMATOLOGY. - ISSN 0925-5710. - 117:1(2023), pp. 16-23. [10.1007/s12185-022-03432-7]

Asciminib as a third line option in chronic myeloid leukemia

Scalzulli, Emilia;Martelli, Maurizio;Breccia, Massimo
2023

Abstract

Unmet needs remain in the treatment of chronic phase chronic myeloid leukemia (CML) in later lines. Sequential use of tyrosine kinase inhibitors (TKIs) is associated with decreased overall survival and emergence of new mutations, particularly the T315I mutation. Among the new drugs developed to overcome resistance and intolerance, the STAMP inhibitor asciminib (which specifically targets the ABL myristoyl pocket) is the first example of a drug that works by allosteric inhibition. This review focuses on its mechanism of action, pharmacokinetic, efficacy, and toxicity, as well as how this drug will change the therapeutic approach for CML patients not eligible to receive other available drugs.
2023
Asciminib; Chronic myeloid leukemia; Later lines
01 Pubblicazione su rivista::01a Articolo in rivista
Asciminib as a third line option in chronic myeloid leukemia / Laganà, Alessandro; Scalzulli, Emilia; Carmosino, Ida; Martelli, Maurizio; Breccia, Massimo. - In: INTERNATIONAL JOURNAL OF HEMATOLOGY. - ISSN 0925-5710. - 117:1(2023), pp. 16-23. [10.1007/s12185-022-03432-7]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1684734
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 3
social impact